Strides Pharma gets USFDA nod for greenfield facility in Singapore

Our Bureau Bengaluru | Updated on March 29, 2019 Published on March 27, 2019

Strides Pharma Science has received USFDA approval for its greenfield oral dosage facility in Singapore.

With the commercialization of its manufacturing facility in Singapore, Strides will join the league of global pharmaceutical companies having a manufacturing and Research and Development footprint in Singapore. Further, the facility will complement Strides’ existing manufacturing base and will help meet increased demand from its fast-growing regulated markets business across US, Australia, UK and Europe, the company said in a statement.

Since Singapore is also amongst the list of designated countries under the Trade Agreements Act (TAA) making it eligible to supply goods under Federal Supply Schedule (FSS) contracts in the US, the manufacturing facility will enable Strides to tap opportunities under various federal government procurement initiatives.

Strides also said that the facility operating at its peak capacity will produce 1.4 billion tablets and hard gelatin capsules and has already been approved by Health Science Authority (HSA) Singapore and Therapeutic Goods Administration (TGA) Australia.

Follow us on Telegram, Facebook, Twitter, Instagram, YouTube and Linkedin. You can also download our Android App or IOS App.

Published on March 27, 2019
This article is closed for comments.
Please Email the Editor